Navigation Links
AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting

Results showed an overall CBR of 52% which compares favorably with the activity of mTOR inhibitors

QUEBEC CITY, QC, June 04, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. , a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its partner, Keryx Biopharmaceuticals presented a poster outlining Phase 1 and Phase 2 results for perifosine, an oral anti-cancer signal transduction inhibitor compound, for the treatment of patients with advanced sarcoma. Results of the Phase 1 and Phase 2 studies of perifosine showed an overall clinical benefit rate (CBR) of 52% which compares favorably with the activity of mTOR inhibitors. The poster titled, "Perifosine (P) an active agent in the treatment of patients with advanced sarcoma": R. Birch, S. Chawla, J. Nemunaitis, P. Savage, P. Kaiser, A. Spira, A. Cervera, E. Middleman, E. Sausville, M. Knowling, I. Henderson, was presented Sunday, June 3, 2007 at the American Society of Clinical Oncology's (ASCO) Annual Meeting currently being held in Chicago, Illinois.

David J. Mazzo, Ph.D., President and CEO of AEterna Zentaris commented, "We are very encouraged by the data from these Phase 1 and Phase 2 trials confirming single agent activity with perifosine in patients with advanced sarcomas, comparable to the activity of mTOR inhibitors."

Background

Perifosine is a novel oral alkylphospholipid that targets the PI3K pathway upstream from mTOR by inhibiting the phosphorylation of Akt. Perifosine's activity against sarcomas has now been evaluated in 145 patients enrolled in one of three Phase 1 trials or four Phase 2 trials. Five of these trials have been published.

    Methods


    Dose categories were as follows:


    -------------------------------------------------------------------------

    Lower Dose                           Higher Dose

    ----------------------------------------------------
'"/>




Page: 1 2 3 4

Related medicine technology :

1. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
2. AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in Los Angeles
3. AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles
5. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial
6. terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. GenoLogics Announces Bioinformatics Partnership with Illumina
9. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
10. Inovio Biomedicals Partners to Present New Data from Two Cancer Immunotherapy Clinical Trials
11. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys Investigational Drug to Treat Cocaine and Methamphetamine Addiction
Post Your Comments:
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com announces ... its catalogue: Global Feminine Hygiene Products Industry ... report analyzes the worldwide markets for Feminine Hygiene Products ... Pads/Towels, Tampons, Panty liners, and Others. The report provides ... , Japan , ...
(Date:8/20/2014)... 2014 Reportlinker.com announces that a new ... The Market for Medical Devices in ... European, Middle Eastern and African markets represent significant ... of its coverage, this study: The Market for ... medical device markets and estimates markets for specific ...
(Date:8/20/2014)... DIEGO , Aug. 20, 2014 Trovagene, ... diagnostics, announced today that results from two clinical studies ... conference for the Company,s urine-based diagnostic test for the ... The IPV conference is scheduled to take place in ... to 25 th . Additionally, a new U.S. ...
Breaking Medicine Technology:Global Feminine Hygiene Products Industry 2Global Feminine Hygiene Products Industry 3Global Feminine Hygiene Products Industry 4Global Feminine Hygiene Products Industry 5Global Feminine Hygiene Products Industry 6Global Feminine Hygiene Products Industry 7Global Feminine Hygiene Products Industry 8Global Feminine Hygiene Products Industry 9Global Feminine Hygiene Products Industry 10Global Feminine Hygiene Products Industry 11Global Feminine Hygiene Products Industry 12Global Feminine Hygiene Products Industry 13Global Feminine Hygiene Products Industry 14Global Feminine Hygiene Products Industry 15Global Feminine Hygiene Products Industry 16Global Feminine Hygiene Products Industry 17Global Feminine Hygiene Products Industry 18Global Feminine Hygiene Products Industry 19Global Feminine Hygiene Products Industry 20Global Feminine Hygiene Products Industry 21Global Feminine Hygiene Products Industry 22Global Feminine Hygiene Products Industry 23Global Feminine Hygiene Products Industry 24Global Feminine Hygiene Products Industry 25Global Feminine Hygiene Products Industry 26The Market for Medical Devices in EMEA 2The Market for Medical Devices in EMEA 3The Market for Medical Devices in EMEA 4The Market for Medical Devices in EMEA 5Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3
... Arnold & Itkin LLP has filed five ... on claims that many of the companies, defective devices ... the attorneys at Arnold & Itkin are ... shoulder surgery. The pumps utilize a catheter to deliver continuous doses ...
... , BEDFORD, Mass., Nov. 11 Hologic, Inc. (Nasdaq: ... at the NASDAQ OMX 23rd Investor Program in London on ... parties are invited to listen to a live audio webcast ... company,s website at www.hologic.com/investor . An archive ...
Cached Medicine Technology:Arnold & Itkin Announces Lawsuits Over Defective Pain Pumps 2Arnold & Itkin Announces Lawsuits Over Defective Pain Pumps 3
(Date:8/20/2014)... Thompson HealthDay Reporter WEDNESDAY, ... fell dramatically during the past two decades, plummeting 57 percent ... shows. An estimated 4 million fewer births occurred among ... from the U.S. Centers for Disease Control and Prevention. ... the report," said Bill Albert, chief program officer of The ...
(Date:8/20/2014)... have discovered that the immune system is defective in people ... why sufferers have ongoing issues with pain. , The research ... could also help to explain why some painkillers may not ... affects up to 10% of the community. There are ... gut pain, which often has the greatest impact on sufferers, ...
(Date:8/20/2014)... Pigs, hearts transplanted into baboons survived for more than ... achieved, researchers report. The work is part of ... shorten transplant waiting lists. In this study, scientists ... The genetic engineering and new methods of suppressing the ... to survive for more than a year. The ...
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. 20, ... grow may help doctors diagnose and treat the most aggressive ... found that the deadliest skin cancers occur most often on ... history of sun exposure. These lesions also grow quickly ... growth -- called "high mitotic rate" -- is associated ...
(Date:8/20/2014)... Tuberculosis is one of the most persistent and deadliest ... million people each year. , Scientists who study tuberculosis ... tuberculosis likely spread from humans in Africa to seals ... America and transmitted it to Native people there before ... Mycobacterial Genomes Reveal Seals as a Source of New ...
Breaking Medicine News(10 mins):Health News:Teen Birth Rate Has Dropped Dramatically in Last Two Decades: CDC 2Health News:Teen Birth Rate Has Dropped Dramatically in Last Two Decades: CDC 3Health News:Pain treatments less effective for those with irritable bowel 2Health News:Pigs' Hearts Beat for a Year in Baboons' Abdomens 2Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 2Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 3Health News:New research shows seals and sea lions likely spread tuberculosis to humans 2Health News:New research shows seals and sea lions likely spread tuberculosis to humans 3
... , , LAS VEGAS, ... assistance program, announced today that it has partnered with the Las Vegas ... have access to the free drug card program. The Chamber has committed ... members to develop additional card distribution sites. , , ...
... YORK, July 28 A record 488 new, innovative ... New York City, according to a new report released today at ... Food and Drug Administration (FDA) or are in human clinical trials. ... Darryl Strawberry, a two-time colon cancer survivor, described his battle against ...
... , , Seniors Group ... Americans , , WASHINGTON, July 28 ... endorsing the plan presented by President Obama and his Congressional allies ... pay for "health care reform." Thair Phillips, the new president of ...
... A new study by psychologists at the University at ... finds that in the aftermath of national trauma, the ... implications for individual well-being and that the kinds of ... psychological outcomes for them. The study, "The Political is ...
... were overcast , TUESDAY, July 28 (HealthDay News) -- A ... and other cognitive problems in people suffering from depression. , ... shift with shifting skies, with more depression linked with less ... exposure and cognition have been paired, stated the authors of ...
... TSX: COM, , , VANCOUVER, July 28 /PRNewswire-FirstCall/ ... announced that it has earned a US$15 million milestone payment ... an affiliate. The milestone was triggered by the submission, by ... Medicines Agency (EMEA) seeking marketing approval for vernakalant (iv) in ...
Cached Medicine News:Health News:Report Shows New York City Companies Playing Key Role In Development of New Medicines for Wide Range of Diseases 2Health News:Report Shows New York City Companies Playing Key Role In Development of New Medicines for Wide Range of Diseases 3Health News:Report Shows New York City Companies Playing Key Role In Development of New Medicines for Wide Range of Diseases 4Health News:RetireSafe Blasts AARP for Supporting Plan to Pay for Health Care on the Backs of Seniors 2Health News:Stories we tell about national trauma reflect our psychological well-being 2Health News:Stories we tell about national trauma reflect our psychological well-being 3Health News:Gloomy Days Dim Cognitive Powers of the Depressed 2Health News:Cardiome Achieves Milestone From Collaboration With Merck Co., Inc. 2Health News:Cardiome Achieves Milestone From Collaboration With Merck Co., Inc. 3
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
... The Self-Cath Closed System is a ... method for safe, simple catheterization designed ... tract infections. It includes a ... The new EasyOff tear tab makes ...
... Self-Cath family of 100% ... a variety of options ... Each catheter is made ... PVC and has smooth ...
... The Self-Cath family ... offers patients a variety ... self-catheterization. Each catheter ... medical grade PVC and ...
Medicine Products: